{"database": "lobbying", "table": "lobbying_activities", "rows": [[3963990, "29a1f11a-d0e7-457c-90c9-e999a1ff4b84", "Q2", "LMH STRATEGIC SOLUTIONS", 401108183, "ALKERMES, INC.", 2026, "second_quarter", "MMM", "Medicare/Medicaid issues. Medicaid drug rebate program. Prescription drug pricing, including MDRP Substance Use Disorder Policy. Implementation of Inflation Reduction Act of 2022. H.R.946: ORPHAN Cures Act. Provide strategic counsel and advocate on issues related to the biopharmaceutical industry generally, and Alkermes, Inc. specifically. Provide guidance and advice regarding mental health, public health and regulatory reform.", "Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE", 0, 0, "2026-07-05T05:48:44-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["3963990"], "units": {}, "query_ms": 0.281398999504745, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}